•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

A05860 Summary:

BILL NOA05860B
 
SAME ASSAME AS S03081-B
 
SPONSORReyes
 
COSPNSRWilliams, Otis, Griffin, Walsh
 
MLTSPNSR
 
Add §396-rrr, Gen Bus L
 
Prohibits selling a drug subject to a shortage for an unconscionably excessive price.
Go to top

A05860 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                         5860--B
 
                               2021-2022 Regular Sessions
 
                   IN ASSEMBLY
 
                                      March 1, 2021
                                       ___________
 
        Introduced  by M. of A. REYES, WILLIAMS -- read once and referred to the
          Committee on Consumer Affairs and Protection -- committee  discharged,
          bill  amended,  ordered  reprinted  as amended and recommitted to said
          committee -- recommitted to the  Committee  on  Consumer  Affairs  and
          Protection  in accordance with Assembly Rule 3, sec. 2 -- reported and
          referred to the Committee  on  Codes  --  committee  discharged,  bill
          amended,  ordered reprinted as amended and recommitted to said commit-
          tee
 
        AN ACT to amend the general business law, in relation to the price goug-
          ing of medicine
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section 1. The general business law is amended by adding a new section
     2  396-rrr to read as follows:
     3    §  396-rrr.  Price  gouging  of  medicine. 1. For the purposes of this
     4  section, "drug subject to a shortage" shall mean  any  drug  or  medical
     5  product  intended  for human use publicly reported as being subject to a
     6  shortage by the U.S.  food  and  drug  administration  on  its  website,
     7  provided,  however, that a drug or medical product shall only be consid-
     8  ered a "drug subject to a shortage" during the period of time that  such
     9  drug or medical product is listed as being subject to a shortage on such
    10  website.
    11    2. No manufacturer, supplier, wholesaler, distributor or retail seller
    12  of  any  drug subject to a shortage shall sell or offer to sell any such
    13  drug subject to a shortage for an amount which represents an unconscion-
    14  ably excessive price.
    15    3. Whether a price is unconscionably excessive is a  question  of  law
    16  for the court.
    17    (a)  The  court's  determination  that a violation of this section has
    18  occurred shall be based on any of the following factors:
    19    (i) that the amount of the excess in price is unconscionably extreme;
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD06581-04-2

        A. 5860--B                          2
 
     1    (ii) that there was an exercise of unfair leverage  or  unconscionable
     2  means; or
     3    (iii)  a  combination of both factors in subparagraphs (i) and (ii) of
     4  this paragraph.
     5    (b) In any proceeding commenced pursuant to subdivision four  of  this
     6  section, prima facie proof that a violation of this section has occurred
     7  shall include evidence that:
     8    (i)  the amount charged represents a gross disparity between the price
     9  of the drug subject to a shortage which was the subject  of  the  trans-
    10  action and their value measured by the price at which such drug was sold
    11  or  offered  for  sale  by the defendant in the usual course of business
    12  immediately prior to the onset of the shortage; or
    13    (ii) the amount charged grossly exceeded the price at which  the  same
    14  or  similar  drug  subject to a shortage was readily obtainable by other
    15  purchasers in the trade area.
    16    (c) A defendant may rebut a prima facie case with evidence that:
    17    (i) the increase in the amount charged preserves the margin of  profit
    18  that  the  defendant  received  for  the same drug subject to a shortage
    19  prior to the onset of the shortage; or
    20    (ii) additional costs not within the control  of  the  defendant  were
    21  imposed on the defendant for the drug subject to a shortage.
    22    4.  Where a violation of this section is alleged to have occurred, the
    23  attorney general may apply in the name of the People of the State of New
    24  York to the supreme court within the judicial  district  in  which  such
    25  violation  is  alleged  to have occurred, on notice of five days, for an
    26  order enjoining or restraining commission or continuance of the  alleged
    27  unlawful  acts.  In  any such proceeding, the court shall impose a civil
    28  penalty in an amount not to  exceed  twenty-five  thousand  dollars  per
    29  violation  or  three  times  the  gross  receipts  for the relevant drug
    30  subject to the shortage, whichever is greater,  and  where  appropriate,
    31  order restitution to aggrieved parties.
    32    § 2. This act shall take effect immediately.
Go to top